ArticleDrug safety2026

Correction: Liver Safety of the Dual Neurokinin‑1/‑3 Receptor Antagonist Elinzanetant.

James H Lewis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.